Results 11 to 20 of about 745,289 (215)
Antibody–drug conjugate: a newly developed biological missile for tumor treatment [PDF]
Frontiers in OncologyAntibody–drug conjugates (ADCs) represent one of the most advanced drug configurations under current research, primarily composed of a monoclonal antibody (mAb), a highly potent cytotoxic payload, and a linker that connects the drug to the antibody.
Zhuoran Tang, Yanchun Xie, Yanping Zeng
doaj +2 more sources
Extracellular payload release from non-internalizing antibody–drug conjugates: mechanisms and linker technologies [PDF]
Drug DeliveryAntibody‒drug conjugates (ADCs) have taken on a significant role in precision oncology. These molecules, referred to as 'biological missiles', can deliver cytotoxic drugs directly to cancer cells.
Chenxi Feng +7 more
doaj +2 more sources
Cancer Medicine, 2019 Antibody‐drug conjugates (ADCs) belong to a promising class of biopharmaceuticals in which target‐killing of tumor cells was achieved by marrying the potency of the cytotoxic payload with the tumor specificity of the antibody.
Baoying Shi +10 more
doaj +2 more sources
Cancer ResearchAn anti-CD276 monoclonal antibody conjugated with both a cytotoxic drug and an immune boosting reagent effectively targets triple-negative breast cancer by inducing tumor cell death and stimulating immune cell infiltration.
Zhuoxin Zhou +7 more
semanticscholar +3 more sources
Antibody-Drug Conjugates Containing Payloads from Marine Origin
Marine Drugs, 2022 Antibody-drug conjugates (ADCs) are an important class of therapeutics for the treatment of cancer. Structurally, an ADC comprises an antibody, which serves as the delivery system, a payload drug that is a potent cytotoxin that kills cancer cells, and a ...
Iván Cheng-Sánchez +4 more
doaj +1 more source
Antibody–Drug Conjugates—A Tutorial Review
Molecules, 2021 Antibody–drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 ADCs currently in clinical development and eleven ADCs (nine containing small ...
Stephanie Baah +2 more
doaj +1 more source
Targeting cancer with antibody-drug conjugates: Promises and challenges
mAbs, 2021 Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the U.S.
Alexis Q. Dean +3 more
doaj +1 more source
Introduction to Antibody-Drug Conjugates
Antibodies, 2021 Antibody-drug conjugates (ADCs) are innovative biopharmaceutical products in which a monoclonal antibody is linked to a small molecule drug with a stable linker.
Mark C. Pettinato
doaj +1 more source
Frontiers in Chemistry, 2022 An efficient Ugi multicomponent reaction with strain promoted azide-alkyne cycloaddition protocol has been utilized in concert or independently to prepare a small family of bioactive zinc(II) dipicolylamine (ZnDPA)-based SN-38 conjugates. With sequential
Ching-Hua Tsai +7 more
doaj +1 more source
Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads [PDF]
ACS Medicinal Chemistry Letters, 2016 The tubulysin class of natural products has attracted much attention from the medicinal chemistry community due to its potent cytotoxicity against a wide range of human cancer cell lines, including significant activity in multidrug-resistant carcinoma models. As a result of their potency, the tubulysins have become an important tool for use in targeted
Carolyn A, Leverett +15 more
openaire +2 more sources